Ben Van Hove
Ben Van Hove is currently Associate director Drug Product Development at Janssen Pharmaceutica NV, heading a group of scientists responsible for the development of solid formulations for small molecules in the clinical stage.
After completing his Master in Pharmaceutical sciences, and an additional master Industrial Pharmaceutical Sciences at the Catholic University of Leuven, Belgium in 2001, he joined Janssen Pharmaceutica NV. He has currently 18 years of experience within the Janssen Pharmaceutical Sciences and Manufacturing Organization, responsible for the CMC activities for both the early as the late stage clinical programs.
He delivered major contributions in the CMC development activities of the following commercialized programs: Yondelis IV (oncology), Zytiga tablets (oncology), Nucynta IR and ER tablets with tamper resistant properties (pain medication), Ceftobiprole (antibiotic), Mebendazole pediatric tablets (helminth infections) and he managed/ is managing multiple programs in the clinical stage.